Joseph Schwartz

InflaRx N.V. (NASDAQ: IFRX) shares are rallying hard Thursday. Here's why.  What Happened: German biopharma InflaRx, which focuses on developing therapies for autoimmune and inflammatory diseases, announced positive data Wednesday from the third cohort of patients in the Phase 2a study...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT), which had a lot riding on its gene therapy candidate for treating Duchenne muscular dystrophy in the new year, are sinking. What Happened: Cambridge, Massachusetts-based Sarepta announced topline results from Part 1 of the Phase 2/3 study of...

Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap from the 1.7% absolute increase in fetal hemoglobin, or HbF, demonstrated at interim readout and...

Biogen Inc (NASDAQ: BIIB) to acquire gene therapy company Nightstar Therapeutics PLC (NASDAQ: NITE). Roche Holdings AG Basel ADR (OTC: RHHBY) agrees to buy Spark Therapeutics Inc (NASDAQ: ONCE). Sarepta Therapeutics Inc (NASDAQ: SRPT) exercises option to buy Myonexus Therapeutics for $165...

Shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) were trading higher by more than 12 percent Wednesday after the company released encouraging clinical trial data. The company's therapy showed a greater improvement in muscle and lung function for people suffering from Pompe, a rare disease...

ProQR Therapeutics NV (NASDAQ: PRQR), a nano-cap pre-clinical stage bio pharmaceutical company engaged in the discovery and development of ribonucleic acid-based therapeutics for the treatment of severe genetic disorders, announced the completion of a phase 1b study Monday, which helped boost...

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) continued to sell off Friday in reaction to the U.S. Food and Drug Administration's letter to physicians warning them against the company's liver disease medicine called Ocaliva. One of the main takeaways from the FDA's letter is the absence of...

Leerink initiated coverage of Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) with an Outperform rating and a $5 price target. New Management As A Catalyst For Growth Leerink analyst Joseph Schwartz noted several opportunities could create a significant amount of shareholder value, including the...

After the release of Ophthotech Corp (NASDAQ: OPHT)'s fourth-quarter results, Leerink weighed in on the possibility of a path forward for Fovista, the company's candidate for the treatment of wet age-related macular degeneration. The Disappointment The company announced disappointing...

Leerink upgraded Sarepta Therapeutics Inc (NASDAQ: SRPT) to Outperform from Market Perform, saying the stock appears to have fully consolidated and reflects reasonable expectations for the Exondys launch. The Backdrop Sarepta Therapeutics has received FDA’s accelerated approval for eteplirsen...

Shares of Sarepta Therapeutics Inc (NASDAQ: SPRT) were under heavy selling pressure following a concerning report released by Leerink's Joseph Schwartz. Schwartz completed a MEDACorp payor survey and the results suggest the reimbursement landscape for Sarepta's therapy for the treatment...

Sarepta Therapeutics Inc (NASDAQ: SRPT), a biopharmaceutical company that focuses on the treatment of rare diseases, such as Duchenne Muscular Dystrophy (DMD), has become one of the most debated stocks of 2016. After bottoming at $8 per share in early 2016 the stock soared as high as $63.73...

Leerink's Joseph Schwartz felt it prudent to take a deep dive into Sarepta Therapeutics Inc's (NASDAQ: SRPT) EXONDYS 51, the company's therapy for the treatment of Duchenne muscular dystrophy (DMD). There are three reasons investors should take a "more cautious view" on...

Leerink analysts Joseph Schwartz and Dae Gon Ha are confident that Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) will gain from MPS 7 treatment ahead of pivotal data. The two analysts boosted their price target to $85 from $80 while rating the stock at Outperform. The brokerage listed four main...

Leerink recently hosted 24 biopharmaceutical companies at a roundtable event. Of the 24 companies, Leerink now rates 20 of them as Outperform. Many of these 20 companies have strong potential catalysts coming relatively soon. Leerink Partners recently hosted a Rare Disease Roundtable that...